Tiny Health Raised $33 Million for Microbiome Data
The company secured funding to scale its clinical research and business-to-business platform for practitioners.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Is now a good time to invest in personalized microbiome or health testing for your household?
Austin-based Tiny Health has raised $33 million in an oversubscribed Series B round, bringing its total funding to $46 million. The capital will support the company's efforts to expand its clinical research initiatives and scale its B2B platform for healthcare providers.
Why it matters
This investment accelerates Tiny Health's objective to make microbiome data actionable for clinical practitioners, addressing a market where chronic conditions affect a large portion of the U.S. population. The company intends to leverage this capital to grow its practitioner education programs and further investigate interventional studies.
Tiny Health utilizes an in-house bioinformatics pipeline and a proprietary dataset of nearly 200,000 microbiome profiles to power its testing. The platform, which has grown 4x in the last year, employs shotgun metagenomic sequencing—a method of sequencing all DNA in a sample—to detect over 120,000 genomes.
The players
Tiny Health
An Austin-based biotechnology company that provides shotgun metagenomic sequencing services and maintains a large proprietary database of microbiome profiles.
B Capital
A venture capital firm that focuses on building and scaling technology companies and led this Series B funding round.
The details
The company leverages shotgun metagenomic sequencing to analyze gut and vaginal microbiomes, identifying a broad range of biological signatures. This data feeds into an AI platform trained on its proprietary dataset of 200,000 profiles, which has already been utilized in four published scientific papers. One recent study demonstrated that microbiome-focused interventions can reduce the odds of infant eczema by 83%.
Timeline
2020: Tiny Health was founded.
2022: The company launched its testing platform.
2025: A published study showed an 83% reduction in infant eczema odds using their intervention.
September 29, 2026: Tiny Health announced its $33 million Series B funding.
The Tech Race
The application of shotgun metagenomic sequencing in personalized medicine represents a shift from static health reporting to actionable clinical interventions. Tiny Health is competing to standardize this data within practitioner-led workflows to address the rising prevalence of chronic conditions.
While the funding scales the company's B2B services for over 6,000 healthcare practitioners, immediate patient access depends on individual clinics adopting the Tiny Health platform. Practitioners and patients should monitor forthcoming clinical trial results as the company advances its newly launched $5 million research program.
The takeaway
Tiny Health is positioning its 200,000-profile database as a standard for clinical microbiome interventions. Interested parties should monitor the outcomes of the company's $5 million Microbiome Research Program for new validation data regarding microbiome-based health outcomes.
Further reading
For more on emerging research in the field, explore the latest Biotech updates.
Live Poll
Is now a good time to invest in personalized microbiome or health testing for your household?
